Datasets:

mathom

/

ct_dataset

like 0

<s>[INST] Provide inclusion criteria for trial id: NCT00416975 [/INST] None </s>

<s>[INST] Provide exclusion criteria for trial id: NCT00416975 [/INST] None </s>

<s>[INST] Provide description for trial id: NCT00416975 [/INST] RATIONALE: Education, based on a patient's risk factors, may help promote breast cancer screening in healthy women. PURPOSE: This randomized clinical trial is studying individualized risk-based education to see how well it promotes breast cancer screening in healthy women compared to standard education. </s>

<s>[INST] Provide title for trial id: NCT00416975 [/INST] Individualized Risk-Based Education in Promoting Breast Cancer Screening in Healthy Women </s>

<s>[INST] Provide the recruitment status for trial id: NCT00416975 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT00416975 [/INST] Breast Cancer </s>

<s>Trial Id: Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients Recruitment Status: Completed Trail description: Primary objective: Determine the impact of the Oncotype DX Recurrence Score (RS) on the treatment recommendation made (administration of chemotherapy or not, in addition to hormonotherapy) in a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population. The impact of Oncotype DX on treatment recommendations can be either a decrease in treatment intensity defined as a change in treatment recommendation from chemotherapy plus hormonal therapy to hormonal therapy alone or an increase in treatment intensity defined as a movement from hormonal therapy alone to the addition of chemotherapy to hormonal therapy. Patients with HR+, N- breast cancer currently represent around 70% of newly diagnosed breast cancers. These are usually good prognosis tumors. However, on the basis of classical clinical and pathological prognostic parameters and markers, the international consensus guidelines recommend treatment with hormone- and chemotherapy in 85-95% of the cases. Considering the natural disease history, such as documented by the EBCTCG meta-analysis, more than 50% of these patients are overtreated, which leads to unnecessary side effects and costs to the health system and to the society. Oncotype DX appears to be well adapted to therapeutic de-escalation as it targets HR+, N- patients and is performed on fixed paraffin embedded tissue (FPET). It is therefore best adapted to daily clinical practice as it does not necessitate any specific surgical procedure or tissue freezing. The prognostic and predictive value of Oncotype DX in ER+, N- patients has been validated on three large adjuvant randomized trials (NASBP B-14, NSABP B-20, and the ATAC study). The test has been commercially available in the USA since 2004, and is being used for more than 50% of the HR+ N- patients in this country. While Oncotype DX has been validated in the USA, it needs to be independently evaluated in France, in the context of the local treatment guidelines and habits, to provide data that are meaningful to the French health system and to the French medical community. Inclusion Criteria: Patients > 18 years old. Pre- or post- menopausal women with breast adenocarcinoma, confirmed by a pathologist and who underwent surgery, with a maximum of 4 weeks between surgery and the 2nd therapeutic decision with Oncotype DX. HR positive (at least ER+) breast cancer patients (defined by a threshold of 10% of the cells IHC + without N- or pN1(mi), Her2 - (IHC0, 1, 2+ or FISH -) Patients must be eligible to receive adjuvant chemotherapy as defined by a good Karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity. Patients must have given a written informed consent. Exclusion Criteria: T3 or T4, HR-, N+ (except pN1 (mi) (sn), Her2+ (IHC 3+ or Fish+) patients. Metastatic patients. Patients who cannot give an informed consent. Patients who cannot receive chemotherapy. Patient who participated in another clinical trial and is still in the exclusion period of any other trial. Mentally disabled patient who has no legal responsibility for herself. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01446185 [/INST] Patients > 18 years old. Pre- or post- menopausal women with breast adenocarcinoma, confirmed by a pathologist and who underwent surgery, with a maximum of 4 weeks between surgery and the 2nd therapeutic decision with Oncotype DX. HR positive (at least ER+) breast cancer patients (defined by a threshold of 10% of the cells IHC + without N- or pN1(mi), Her2 - (IHC0, 1, 2+ or FISH -) Patients must be eligible to receive adjuvant chemotherapy as defined by a good Karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity. Patients must have given a written informed consent. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01446185 [/INST] T3 or T4, HR-, N+ (except pN1 (mi) (sn), Her2+ (IHC 3+ or Fish+) patients. Metastatic patients. Patients who cannot give an informed consent. Patients who cannot receive chemotherapy. Patient who participated in another clinical trial and is still in the exclusion period of any other trial. Mentally disabled patient who has no legal responsibility for herself. </s>

<s>[INST] Provide description for trial id: NCT01446185 [/INST] Primary objective: Determine the impact of the Oncotype DX Recurrence Score (RS) on the treatment recommendation made (administration of chemotherapy or not, in addition to hormonotherapy) in a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population. The impact of Oncotype DX on treatment recommendations can be either a decrease in treatment intensity defined as a change in treatment recommendation from chemotherapy plus hormonal therapy to hormonal therapy alone or an increase in treatment intensity defined as a movement from hormonal therapy alone to the addition of chemotherapy to hormonal therapy. Patients with HR+, N- breast cancer currently represent around 70% of newly diagnosed breast cancers. These are usually good prognosis tumors. However, on the basis of classical clinical and pathological prognostic parameters and markers, the international consensus guidelines recommend treatment with hormone- and chemotherapy in 85-95% of the cases. Considering the natural disease history, such as documented by the EBCTCG meta-analysis, more than 50% of these patients are overtreated, which leads to unnecessary side effects and costs to the health system and to the society. Oncotype DX appears to be well adapted to therapeutic de-escalation as it targets HR+, N- patients and is performed on fixed paraffin embedded tissue (FPET). It is therefore best adapted to daily clinical practice as it does not necessitate any specific surgical procedure or tissue freezing. The prognostic and predictive value of Oncotype DX in ER+, N- patients has been validated on three large adjuvant randomized trials (NASBP B-14, NSABP B-20, and the ATAC study). The test has been commercially available in the USA since 2004, and is being used for more than 50% of the HR+ N- patients in this country. While Oncotype DX has been validated in the USA, it needs to be independently evaluated in France, in the context of the local treatment guidelines and habits, to provide data that are meaningful to the French health system and to the French medical community. </s>

<s>[INST] Provide title for trial id: NCT01446185 [/INST] Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients </s>

<s>[INST] Provide the recruitment status for trial id: NCT01446185 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT01446185 [/INST] Breast Cancer </s>

<s>Trial Id: Know Your Risk: Assessment at Screening for Breast Cancer - Pilot Study Recruitment Status: Completed Trail description: The purpose of this pilot study is to evaluate a decision support website (RealRisks) designed to inform patients about breast cancer chemoprevention. It is coupled with a physician-centered (BNAV) decision support website as part of clinical workflow in the primary care setting. The investigator hypothesizes that improving accuracy of breast cancer risk perception and understanding of the risks/benefits of chemoprevention will enhance informed decision-making and uptake of breast cancer prevention strategies in the primary care setting. Inclusion Criteria: 5-year breast risk of 1.67% or lifetime risk of 20% according to the Gail model The participant understands and is willing to provide informed consent in English or Spanish Has a primary care provider at Columbia University Medical Center (CUMC) / New York-Presbyterian Hospital Exclusion Criteria: Prior use of a selective estrogen receptor modulator (SERM) or aromatase inhibitor (AI) for chemoprevention Prior history of breast cancer </s>

<s>[INST] Provide inclusion criteria for trial id: NCT02954900 [/INST] 5-year breast risk of 1.67% or lifetime risk of 20% according to the Gail model The participant understands and is willing to provide informed consent in English or Spanish Has a primary care provider at Columbia University Medical Center (CUMC) / New York-Presbyterian Hospital </s>

<s>[INST] Provide exclusion criteria for trial id: NCT02954900 [/INST] Prior use of a selective estrogen receptor modulator (SERM) or aromatase inhibitor (AI) for chemoprevention Prior history of breast cancer </s>

<s>[INST] Provide description for trial id: NCT02954900 [/INST] The purpose of this pilot study is to evaluate a decision support website (RealRisks) designed to inform patients about breast cancer chemoprevention. It is coupled with a physician-centered (BNAV) decision support website as part of clinical workflow in the primary care setting. The investigator hypothesizes that improving accuracy of breast cancer risk perception and understanding of the risks/benefits of chemoprevention will enhance informed decision-making and uptake of breast cancer prevention strategies in the primary care setting. </s>

<s>[INST] Provide title for trial id: NCT02954900 [/INST] Know Your Risk: Assessment at Screening for Breast Cancer - Pilot Study </s>

<s>[INST] Provide the recruitment status for trial id: NCT02954900 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT02954900 [/INST] Breast Neoplasms </s>

<s>Trial Id: Transgender and Gender-Diverse Breast Cancer Screening Pilot Recruitment Status: Recruiting Trail description: This investigation is a prospective breast cancer screening study open to all transgender and gender-diverse persons (regardless of sex assigned at birth). Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with gender-affirming therapy and family cancer history and 2) investigate TGD persons perceptions and experiences in the breast cancer screening program, and 3) identify individual and systems-level barriers to breast cancer screening. Inclusion Criteria: None Exclusion Criteria: None </s>

<s>[INST] Provide inclusion criteria for trial id: NCT06383026 [/INST] None </s>

<s>[INST] Provide exclusion criteria for trial id: NCT06383026 [/INST] None </s>

<s>[INST] Provide description for trial id: NCT06383026 [/INST] This investigation is a prospective breast cancer screening study open to all transgender and gender-diverse persons (regardless of sex assigned at birth). Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with gender-affirming therapy and family cancer history and 2) investigate TGD persons perceptions and experiences in the breast cancer screening program, and 3) identify individual and systems-level barriers to breast cancer screening. </s>

<s>[INST] Provide title for trial id: NCT06383026 [/INST] Transgender and Gender-Diverse Breast Cancer Screening Pilot </s>

<s>[INST] Provide the recruitment status for trial id: NCT06383026 [/INST] Recruiting </s>

<s>[INST] Provide the medical condition for trial id: NCT06383026 [/INST] Breast Cancer </s>

<s>Trial Id: To Enhance Breast Cancer Survivorship of Asian Americans Recruitment Status: Completed Trail description: The purpose of this randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience. Inclusion Criteria: Self-reported Asian American women aged 21 years and older who identify their sub-ethnicity as Chinese, Korean, or Japanese Have had a breast cancer diagnosis Can read and write English, Mandarin Chinese, Korean or Japanese Have access to the Internet through computers or mobile devices (smart phones and tablets) Exclusion Criteria: Those under 21 years old are excluded because their cancer experience would be different from adults </s>

<s>[INST] Provide inclusion criteria for trial id: NCT02803593 [/INST] Self-reported Asian American women aged 21 years and older who identify their sub-ethnicity as Chinese, Korean, or Japanese Have had a breast cancer diagnosis Can read and write English, Mandarin Chinese, Korean or Japanese Have access to the Internet through computers or mobile devices (smart phones and tablets) </s>

<s>[INST] Provide exclusion criteria for trial id: NCT02803593 [/INST] Those under 21 years old are excluded because their cancer experience would be different from adults </s>

<s>[INST] Provide description for trial id: NCT02803593 [/INST] The purpose of this randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience. </s>

<s>[INST] Provide title for trial id: NCT02803593 [/INST] To Enhance Breast Cancer Survivorship of Asian Americans </s>

<s>[INST] Provide the recruitment status for trial id: NCT02803593 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT02803593 [/INST] Breast Cancer </s>

<s>Trial Id: Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening Recruitment Status: Recruiting Trail description: This research will compare the absolute volumes of the upper extremity using both the LymphaTech Scanner and Perometer in a cohort of patients with a history of invasive or in-situ carcinoma of the breast. Inclusion Criteria: Participants must have histologically or cytologically confirmed invasive or in-situ carcinoma of the breast and will undergo unilateral breast cancer surgery Age >18 years. Ability to understand and the willingness to verbally consent to the trial Exclusion Criteria: History of primary lymphedema. Any patient with a current case of cellulitis. Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Participants unable to abduct upper-extremity perpendicular to body or to stand comfortably without aid for several minutes, both of which are necessary to perform a LymphaTech Scan </s>

<s>[INST] Provide inclusion criteria for trial id: NCT03861975 [/INST] Participants must have histologically or cytologically confirmed invasive or in-situ carcinoma of the breast and will undergo unilateral breast cancer surgery Age >18 years. Ability to understand and the willingness to verbally consent to the trial </s>

<s>[INST] Provide exclusion criteria for trial id: NCT03861975 [/INST] History of primary lymphedema. Any patient with a current case of cellulitis. Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Participants unable to abduct upper-extremity perpendicular to body or to stand comfortably without aid for several minutes, both of which are necessary to perform a LymphaTech Scan </s>

<s>[INST] Provide description for trial id: NCT03861975 [/INST] This research will compare the absolute volumes of the upper extremity using both the LymphaTech Scanner and Perometer in a cohort of patients with a history of invasive or in-situ carcinoma of the breast. </s>

<s>[INST] Provide title for trial id: NCT03861975 [/INST] Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening </s>

<s>[INST] Provide the recruitment status for trial id: NCT03861975 [/INST] Recruiting </s>

<s>[INST] Provide the medical condition for trial id: NCT03861975 [/INST] Breast Cancer </s>

<s>Trial Id: Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer Recruitment Status: Completed Trail description: The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section Hematoxylin and Eosin (H&E) and IHC staining. Inclusion Criteria: Male or Female patients, over the age of 18, diagnosed pre-surgically with T1 or T2 breast cancer and scheduled for surgery including sentinel node dissection. Patients who have read and understand the informed consent form and are capable and willing to provide written informed consent. Exclusion Criteria: Patients diagnosed pre-surgically with large or locally advanced (T3 and T4) breast cancers. Patients diagnosed with inflammatory breast cancer. Patients diagnosed with ductal carcinoma in situ (DCIS) when breast conserving is to be done. Patients who are pregnant, as confirmed by a patient/treating physician interview. Patients with suspicious palpable axillary lymph nodes. Patients currently being treated for or previously diagnosed with, another type of carcinoma. Patients who have undergone prior non-oncologic breast surgery or axillary surgery. Patients who have received pre-operative systemic therapy. Patients who are incapable of providing written informed consent. Patients who have been judged to be inappropriate by a medical care provider (i.e. surgeon, oncologist, pathologists, etc.). </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01136369 [/INST] Male or Female patients, over the age of 18, diagnosed pre-surgically with T1 or T2 breast cancer and scheduled for surgery including sentinel node dissection. Patients who have read and understand the informed consent form and are capable and willing to provide written informed consent. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01136369 [/INST] Patients diagnosed pre-surgically with large or locally advanced (T3 and T4) breast cancers. Patients diagnosed with inflammatory breast cancer. Patients diagnosed with ductal carcinoma in situ (DCIS) when breast conserving is to be done. Patients who are pregnant, as confirmed by a patient/treating physician interview. Patients with suspicious palpable axillary lymph nodes. Patients currently being treated for or previously diagnosed with, another type of carcinoma. Patients who have undergone prior non-oncologic breast surgery or axillary surgery. Patients who have received pre-operative systemic therapy. Patients who are incapable of providing written informed consent. Patients who have been judged to be inappropriate by a medical care provider (i.e. surgeon, oncologist, pathologists, etc.). </s>

<s>[INST] Provide description for trial id: NCT01136369 [/INST] The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to permanent section Hematoxylin and Eosin (H&E) and IHC staining. </s>

<s>[INST] Provide title for trial id: NCT01136369 [/INST] Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer </s>

<s>[INST] Provide the recruitment status for trial id: NCT01136369 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT01136369 [/INST] Breast Neoplasms, Breast Diseases </s>

<s>Trial Id: Catheter Guided Chemo-infusion in Breast Cancer Recruitment Status: Not yet recruiting Trail description: In the present prospective study, we will analyze the outcome of image-guided delivery of intra-arterially infused chemotherapeutic drugs for patients with breast cancer in III, IV stages. Inclusion Criteria: Adult female had stage III,IV breast cancer. Female had received no prior chemotherapy, radiotherapy, or definitive surgical therapy for breast cancer. Patient had adequate organ function. Exclusion Criteria: Patients known to have absolute contraindications for contrast. Patient known to have systemic organ failure. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT05661656 [/INST] Adult female had stage III,IV breast cancer. Female had received no prior chemotherapy, radiotherapy, or definitive surgical therapy for breast cancer. Patient had adequate organ function. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT05661656 [/INST] Patients known to have absolute contraindications for contrast. Patient known to have systemic organ failure. </s>

<s>[INST] Provide description for trial id: NCT05661656 [/INST] In the present prospective study, we will analyze the outcome of image-guided delivery of intra-arterially infused chemotherapeutic drugs for patients with breast cancer in III, IV stages. </s>

<s>[INST] Provide title for trial id: NCT05661656 [/INST] Catheter Guided Chemo-infusion in Breast Cancer </s>

<s>[INST] Provide the recruitment status for trial id: NCT05661656 [/INST] Not yet recruiting </s>

<s>[INST] Provide the medical condition for trial id: NCT05661656 [/INST] Breast Cancer </s>

<s>Trial Id: Reliability And Validity Study Of "The Evaluation Tool For Myofascial Adhesions In Patients After Breast Cancer" In Turkish Language Recruitment Status: Not yet recruiting Trail description: The aim of this observational study is to translate the MAP-BC Evaluation Tool into Turkish by adapting it to Turkish society and to conduct a validity and reliability study in women who have received breast cancer treatment. The main questions it aims to answer are: Are the same researcher's MAP-BC Evaluation Tool results similar at intervals to detect myofascial adhesions in breast cancer patients in Turkish population? Are the different researchers' MAP-BC Evaluation Tool results similar to detect myofascial adhesions in breast cancer patients in Turkish population? After comparing the results of Turkish version of both The Patient and Observer Scar Assessment Scale Observer Subscale and MAP-BC Evaluation Tool, is there a sufficient correlation between them? Inclusion Criteria: None Exclusion Criteria: None </s>

<s>[INST] Provide inclusion criteria for trial id: NCT05923164 [/INST] None </s>

<s>[INST] Provide exclusion criteria for trial id: NCT05923164 [/INST] None </s>

<s>[INST] Provide description for trial id: NCT05923164 [/INST] The aim of this observational study is to translate the MAP-BC Evaluation Tool into Turkish by adapting it to Turkish society and to conduct a validity and reliability study in women who have received breast cancer treatment. The main questions it aims to answer are: Are the same researcher's MAP-BC Evaluation Tool results similar at intervals to detect myofascial adhesions in breast cancer patients in Turkish population? Are the different researchers' MAP-BC Evaluation Tool results similar to detect myofascial adhesions in breast cancer patients in Turkish population? After comparing the results of Turkish version of both The Patient and Observer Scar Assessment Scale Observer Subscale and MAP-BC Evaluation Tool, is there a sufficient correlation between them? </s>

<s>[INST] Provide title for trial id: NCT05923164 [/INST] Reliability And Validity Study Of "The Evaluation Tool For Myofascial Adhesions In Patients After Breast Cancer" In Turkish Language </s>

<s>[INST] Provide the recruitment status for trial id: NCT05923164 [/INST] Not yet recruiting </s>

<s>[INST] Provide the medical condition for trial id: NCT05923164 [/INST] Breast Cancer, Upper Extremity Dysfunction, Tissue Adhesion </s>

<s>Trial Id: Breast Cancer Trials Education Program Recruitment Status: Completed Trail description: The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation. Inclusion Criteria: Self-Identified as an African American or a Hispanic American female Speak English and/or Spanish Mentally and Physically capable of completing the consenting process Exclusion Criteria: None </s>

<s>[INST] Provide inclusion criteria for trial id: NCT02808598 [/INST] Self-Identified as an African American or a Hispanic American female Speak English and/or Spanish Mentally and Physically capable of completing the consenting process </s>

<s>[INST] Provide exclusion criteria for trial id: NCT02808598 [/INST] None </s>

<s>[INST] Provide description for trial id: NCT02808598 [/INST] The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation. </s>

<s>[INST] Provide title for trial id: NCT02808598 [/INST] Breast Cancer Trials Education Program </s>

<s>[INST] Provide the recruitment status for trial id: NCT02808598 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT02808598 [/INST] Breast Cancer </s>

<s>Trial Id: The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study Recruitment Status: Recruiting Trail description: The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is: The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers. Researchers will investigate the features, survival associated factors and other relevant factors of this population. Inclusion Criteria: Biological sex is male; Microscopically diagnosed as primary breast cancer. Exclusion Criteria: Presence of skin-origin malignancy on the breast. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT06220630 [/INST] Biological sex is male; Microscopically diagnosed as primary breast cancer. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT06220630 [/INST] Presence of skin-origin malignancy on the breast. </s>

<s>[INST] Provide description for trial id: NCT06220630 [/INST] The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is: The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers. Researchers will investigate the features, survival associated factors and other relevant factors of this population. </s>

<s>[INST] Provide title for trial id: NCT06220630 [/INST] The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world Study </s>

<s>[INST] Provide the recruitment status for trial id: NCT06220630 [/INST] Recruiting </s>

<s>[INST] Provide the medical condition for trial id: NCT06220630 [/INST] Breast Cancer </s>

<s>Trial Id: Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS) Recruitment Status: Completed Trail description: This study, which is designed according to the experimental model with randomized pre-test and post-test control group, will be carried out with Syrian women who apply to Empowered Migrant Health Center in İstanbul province, Sultanbeyli district, where Syria citizens are immigranted. The population of the study consisted of all Syrian women aged 40-69 under temporary protection who came to the Empowered Migrant Health Center at the time of the research. The working group will be composed of 80 Syrian women who meet the selection criteria. According to the sources, the frequency of breast cancer screening in Turkey is taken as 15%; For the study at 95% confidence level, d=0,6 was taken and n=136 sample size was taken. Considering that there may be those who left during the research period, 14 women will be taken as substitutes and the sample will be completed to a total of 150 in order to increase the power of representing the universe. A personal questionnaire prepared by the researcher in line with the literature, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, will be administered to Syrian women under temporary protection who applied to the empowered migrant health center and agreed to participate in the study.According to the sample pool formed by the women included in the study, the participants were assigned to 2 groups as experiment and control with the "Research Randomizer" program. Each group will be determined as 75 people. A 4-week training program will be applied to the experimental group. The women in the experimental group will be given a self-breast examination control calendar after their first training. Afterwards, motivational interviews will be held once a month for the second and third months. A "Nurse-managed screening consultancy telephone support line" will be established for Syrian women within the scope of the Nurse Navigation Program. Reminder phone calls will be made 4 times a week. Personal questionnaire, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, Post-Training Screening Behavior Follow-up Form will be administered to the experimental and control groups as a post-test. Inclusion Criteria: Being between the ages of 40-69. Being a woman. Not having been diagnosed with breast cancer. Not doing BSE on a regular basis every month. Not having had CME and mammography in the last three years. Not to be pregnant, breastfeeding or postpartum. No history of breast cancer. Not having received training on breast cancer. To agree to participate in the research. Absence of a mental illness. Being literate, accessible and communicative. Not having a communication barrier Being registered with Sultanbeyli Empowered Migrant Health Center Exclusion Criteria: Having a problem with breast cancer before. Having BSE, CBE or Mammography at regular intervals. Having had a mastectomy for any reason. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT04966377 [/INST] Being between the ages of 40-69. Being a woman. Not having been diagnosed with breast cancer. Not doing BSE on a regular basis every month. Not having had CME and mammography in the last three years. Not to be pregnant, breastfeeding or postpartum. No history of breast cancer. Not having received training on breast cancer. To agree to participate in the research. Absence of a mental illness. Being literate, accessible and communicative. Not having a communication barrier Being registered with Sultanbeyli Empowered Migrant Health Center </s>

<s>[INST] Provide exclusion criteria for trial id: NCT04966377 [/INST] Having a problem with breast cancer before. Having BSE, CBE or Mammography at regular intervals. Having had a mastectomy for any reason. </s>

<s>[INST] Provide description for trial id: NCT04966377 [/INST] This study, which is designed according to the experimental model with randomized pre-test and post-test control group, will be carried out with Syrian women who apply to Empowered Migrant Health Center in İstanbul province, Sultanbeyli district, where Syria citizens are immigranted. The population of the study consisted of all Syrian women aged 40-69 under temporary protection who came to the Empowered Migrant Health Center at the time of the research. The working group will be composed of 80 Syrian women who meet the selection criteria. According to the sources, the frequency of breast cancer screening in Turkey is taken as 15%; For the study at 95% confidence level, d=0,6 was taken and n=136 sample size was taken. Considering that there may be those who left during the research period, 14 women will be taken as substitutes and the sample will be completed to a total of 150 in order to increase the power of representing the universe. A personal questionnaire prepared by the researcher in line with the literature, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, will be administered to Syrian women under temporary protection who applied to the empowered migrant health center and agreed to participate in the study.According to the sample pool formed by the women included in the study, the participants were assigned to 2 groups as experiment and control with the "Research Randomizer" program. Each group will be determined as 75 people. A 4-week training program will be applied to the experimental group. The women in the experimental group will be given a self-breast examination control calendar after their first training. Afterwards, motivational interviews will be held once a month for the second and third months. A "Nurse-managed screening consultancy telephone support line" will be established for Syrian women within the scope of the Nurse Navigation Program. Reminder phone calls will be made 4 times a week. Personal questionnaire, Health Belief Model Scale, Mammography Self-Efficacy Scale, Champion Breast Cancer Fear Scale, Breast Self Examination Checklist Form, Post-Training Screening Behavior Follow-up Form will be administered to the experimental and control groups as a post-test. </s>

<s>[INST] Provide title for trial id: NCT04966377 [/INST] Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS) </s>

<s>[INST] Provide the recruitment status for trial id: NCT04966377 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT04966377 [/INST] Breast Cancer </s>

<s>Trial Id: A Pilot Study of Working Women and Breast Cancer Recruitment Status: Completed Trail description: The purpose of this research is to better understand the relationship between employment and breast cancer. Research is being conducted to understand how workplace factors influence breast cancer patients' ability to adhere to recommended cancer treatment and effectively recover from cancer. Investigators hope to use the findings from the study to help working breast cancer survivors make informed decisions about treatment and employment in collaboration with their employers and healthcare providers. Inclusion Criteria: Women age 18-65 Working at least 20 hours per week Currently patients of the University of Kentucky Markey Cancer Center Are able to read, write, and communicate in English Have reliable telephone or Internet/Web access in or outside the home Exclusion Criteria: Self-employed Unemployed Cognitively impaired </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01914614 [/INST] Women age 18-65 Working at least 20 hours per week Currently patients of the University of Kentucky Markey Cancer Center Are able to read, write, and communicate in English Have reliable telephone or Internet/Web access in or outside the home </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01914614 [/INST] Self-employed Unemployed Cognitively impaired </s>

<s>[INST] Provide description for trial id: NCT01914614 [/INST] The purpose of this research is to better understand the relationship between employment and breast cancer. Research is being conducted to understand how workplace factors influence breast cancer patients' ability to adhere to recommended cancer treatment and effectively recover from cancer. Investigators hope to use the findings from the study to help working breast cancer survivors make informed decisions about treatment and employment in collaboration with their employers and healthcare providers. </s>

<s>[INST] Provide title for trial id: NCT01914614 [/INST] A Pilot Study of Working Women and Breast Cancer </s>

<s>[INST] Provide the recruitment status for trial id: NCT01914614 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT01914614 [/INST] Breast Cancer </s>

<s>Trial Id: A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer Recruitment Status: Unknown status Trail description: The purpose of this study is to evaluate the overall response rate, toxicity, progression free survival and quality of life of chemotherapy with docetaxel and oxaliplatin in recurrent or metastatic breast cancer. Inclusion Criteria: Women aged : 20~70 years WHO (ECOG) performance status 0-2 Patients with measurable lesion assessed by imaging using the RECIST (Response Evaluation Criteria In Solid Tumor) guideline patients had previously not received chemotherapy of recurrent or metastatic lesion. Have given written informed consent and are available for prolonged follow-up Exclusion Criteria: Patients with previous chemotherapy for recurrent breast cancer Breast cancer recurrence within 12 months after taxane treatment Her-2/neu expression breast cancer Patients with malignancies (other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell, squamous cell carcinoma of the skin. Brain metastasis uncontrolled infection, medically uncontrollable heart disease other serious medical illness or prior malignancies Pregnant or lactating women were excluded. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01351597 [/INST] Women aged : 20~70 years WHO (ECOG) performance status 0-2 Patients with measurable lesion assessed by imaging using the RECIST (Response Evaluation Criteria In Solid Tumor) guideline patients had previously not received chemotherapy of recurrent or metastatic lesion. Have given written informed consent and are available for prolonged follow-up </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01351597 [/INST] Patients with previous chemotherapy for recurrent breast cancer Breast cancer recurrence within 12 months after taxane treatment Her-2/neu expression breast cancer Patients with malignancies (other than breast cancer) within the last 5 years, except for adequately treated in situ carcinoma of the cervix or basal cell, squamous cell carcinoma of the skin. Brain metastasis uncontrolled infection, medically uncontrollable heart disease other serious medical illness or prior malignancies Pregnant or lactating women were excluded. </s>

<s>[INST] Provide description for trial id: NCT01351597 [/INST] The purpose of this study is to evaluate the overall response rate, toxicity, progression free survival and quality of life of chemotherapy with docetaxel and oxaliplatin in recurrent or metastatic breast cancer. </s>

<s>[INST] Provide title for trial id: NCT01351597 [/INST] A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer </s>

<s>[INST] Provide the recruitment status for trial id: NCT01351597 [/INST] Unknown status </s>

<s>[INST] Provide the medical condition for trial id: NCT01351597 [/INST] Recurrent Breast Cancer, Metastatic Breast Cancer </s>

<s>Trial Id: [18F] F-GLN by PET/CT in Breast Cancer Recruitment Status: Recruiting Trail description: Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC). This is an observational study; [18F]F-GLN PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the [18F]F-GLN PET/CT results, treatment decisions are made by the treating physicians based upon clinical criteria. [18F]F-GLN PET/CT imaging sessions will include an injection of [18F]F-GLN. Metabolism data will be collected. Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of [18F]F-GLN in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of [18F]F-GLN will also be evaluated in all subjects. Inclusion Criteria: Participants will be ≥ 18 years of age Known or suspected primary or metastatic breast cancer. At least one lesion ≥ 1.5 cm that is seen on standard imaging (e.g. CT, MRI, mammogram, ultrasound, FDG-PET/CT). Only one type of imaging is required to show a lesion. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria: Females who are pregnant or breast feeding at the time of screening; a urine pregnancy test will be performed in women of child-bearing potential at screening. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician. Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT03863457 [/INST] Participants will be ≥ 18 years of age Known or suspected primary or metastatic breast cancer. At least one lesion ≥ 1.5 cm that is seen on standard imaging (e.g. CT, MRI, mammogram, ultrasound, FDG-PET/CT). Only one type of imaging is required to show a lesion. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT03863457 [/INST] Females who are pregnant or breast feeding at the time of screening; a urine pregnancy test will be performed in women of child-bearing potential at screening. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician. Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study. </s>